Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
J Lipid Res. 2017 Nov;58(11):2162-2170. doi: 10.1194/jlr.M079822. Epub 2017 Sep 4.
HDL cholesterol (HDL-C) remains a superior biochemical predictor of CVD risk, but its genetic basis is incompletely defined. In patients with extreme HDL-C concentrations, we concurrently evaluated the contributions of multiple large- and small-effect genetic variants. In a discovery cohort of 255 unrelated lipid clinic patients with extreme HDL-C levels, we used a targeted next-generation sequencing panel to evaluate rare variants in known HDL metabolism genes, simultaneously with common variants bundled into a polygenic trait score. Two additional cohorts were used for validation and included 1,746 individuals from the Montréal Heart Institute Biobank and 1,048 individuals from the University of Pennsylvania. Findings were consistent between cohorts: we found rare heterozygous large-effect variants in 18.7% and 10.9% of low- and high-HDL-C patients, respectively. We also found common variant accumulation, indicated by extreme polygenic trait scores, in an additional 12.8% and 19.3% of overall cases of low- and high-HDL-C extremes, respectively. Thus, the genetic basis of extreme HDL-C concentrations encountered clinically is frequently polygenic, with contributions from both rare large-effect and common small-effect variants. Multiple types of genetic variants should be considered as contributing factors in patients with extreme dyslipidemia.
高密度脂蛋白胆固醇(HDL-C)仍然是 CVD 风险的优越生化预测指标,但它的遗传基础尚未完全确定。在 HDL-C 浓度极高的患者中,我们同时评估了多种大效应和小效应遗传变异的贡献。在一个由 255 名无血缘关系的血脂异常门诊患者组成的发现队列中,我们使用靶向下一代测序panel 评估了已知 HDL 代谢基因中的罕见变异,同时将常见变异捆绑成一个多基因特征评分。另外两个队列用于验证,包括来自蒙特利尔心脏研究所生物库的 1746 名个体和宾夕法尼亚大学的 1048 名个体。研究结果在队列之间是一致的:我们分别在低 HDL-C 和高 HDL-C 患者中发现了 18.7%和 10.9%的罕见杂合大效应变异。我们还发现了常见变异的积累,表现为极端的多基因特征评分,分别在低 HDL-C 和高 HDL-C 极端情况的另外 12.8%和 19.3%的总病例中。因此,临床上遇到的极端 HDL-C 浓度的遗传基础通常是多基因的,既有罕见的大效应变异,也有常见的小效应变异。在患有极端血脂异常的患者中,应考虑多种类型的遗传变异作为致病因素。